$EVOK
Evoke Pharma Inc

2016 Q4 Form 10-Q Financial Statement

#000156459016028633 Filed on November 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2015 Q4 2015 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $820.0K $840.0K $820.0K
YoY Change -2.38% 13.51% 12.33%
% of Gross Profit
Research & Development $1.502M $1.708M $1.838M
YoY Change -12.07% -21.51% -40.49%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.502M $1.708M $1.838M
YoY Change -12.07% -21.51% -51.91%
Operating Profit
YoY Change
Interest Expense -$70.00K $78.42K
YoY Change 600.0% 1227.87%
% of Operating Profit
Other Income/Expense, Net $800.0K
YoY Change
Pretax Income -$1.530M -$2.620M -$2.740M
YoY Change -41.6% -10.27% -28.46%
Income Tax
% Of Pretax Income
Net Earnings -$1.527M -$2.624M -$2.735M
YoY Change -41.8% -10.13% -28.49%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$124.1K -$367.5K -$422.2K
COMMON SHARES
Basic Shares Outstanding 12.35M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2015 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.010M $8.690M $10.74M
YoY Change 3.68% -38.63% -11.82%
Cash & Equivalents $9.007M $8.691M $10.74M
Short-Term Investments
Other Short-Term Assets $7.997K $830.0K $940.0K
YoY Change -99.04% 414.14% -16.81%
Inventory
Prepaid Expenses $833.3K
Receivables
Other Receivables
Total Short-Term Assets $9.283M $9.524M $11.67M
YoY Change -2.54% -37.54% -12.31%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $7.997K $10.00K
YoY Change 25.05% -84.92% -87.89%
Total Long-Term Assets $7.221K $7.997K $10.00K
YoY Change -9.7% -84.92% -87.89%
TOTAL ASSETS
Total Short-Term Assets $9.283M $9.524M $11.67M
Total Long-Term Assets $7.221K $7.997K $10.00K
Total Assets $9.290M $9.532M $11.68M
YoY Change -2.54% -37.7% -12.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $480.0K $930.0K $1.340M
YoY Change -48.39% -7.92% 27.62%
Accrued Expenses $930.0K $760.0K $670.0K
YoY Change 22.37% 8.57% 4.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $146.1K $0.00
YoY Change -100.0% 15.18%
Total Short-Term Liabilities $1.410M $1.834M $2.006M
YoY Change -23.14% -0.73% 19.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $4.233M $4.369M
YoY Change -100.0% 0.87%
Other Long-Term Liabilities $4.100M
YoY Change
Total Long-Term Liabilities $4.100M $4.233M $4.369M
YoY Change -3.14% 0.87% 43587.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.410M $1.834M $2.006M
Total Long-Term Liabilities $4.100M $4.233M $4.369M
Total Liabilities $5.510M $6.067M $6.375M
YoY Change -9.19% 0.38% 274.96%
SHAREHOLDERS EQUITY
Retained Earnings -$58.81M -$48.06M -$45.44M
YoY Change 22.36% 33.73% 37.61%
Common Stock $62.60M $51.53M $50.74M
YoY Change 21.49% 14.18% 8305004.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.788M $3.465M $5.308M
YoY Change
Total Liabilities & Shareholders Equity $9.294M $9.532M $11.68M
YoY Change -2.5% -37.42% -12.76%

Cashflow Statement

Concept 2016 Q4 2015 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$1.527M -$2.624M -$2.735M
YoY Change -41.8% -10.13% -28.49%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.370M -$2.460M -$2.500M
YoY Change -44.31% -2.38% -36.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K 400.0K 3.360M
YoY Change -102.5% -91.11% 8300.0%
NET CHANGE
Cash From Operating Activities -1.370M -2.460M -2.500M
Cash From Investing Activities
Cash From Financing Activities -10.00K 400.0K 3.360M
Net Change In Cash -1.380M -2.060M 860.0K
YoY Change -33.01% -204.04% -122.22%
FREE CASH FLOW
Cash From Operating Activities -$1.370M -$2.460M -$2.500M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 evok Warrant Liability
WarrantLiability
5098404
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8691155
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
833276
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4626373
evok Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
13168802
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9026825
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12350360
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
51524821
evok Financing Costs Related To Warrant Liability
FinancingCostsRelatedToWarrantLiability
533692
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6494845
us-gaap Share Based Compensation
ShareBasedCompensation
1298279
us-gaap Share Based Compensation
ShareBasedCompensation
1127813
us-gaap Paid In Kind Interest
PaidInKindInterest
120889
us-gaap Paid In Kind Interest
PaidInKindInterest
45521
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
9227
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-408030
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4405
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-676745
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7338098
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
4500000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
198945
CY2016Q3 evok Financing Costs Related To Warrant Liability
FinancingCostsRelatedToWarrantLiability
533692
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
358023
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1688727
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14155809
evok Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
369863
us-gaap Interest Paid
InterestPaid
169813
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
137812
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0114
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.00
CY2016Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2016Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2016Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
CY2015Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
CY2016Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2016Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4655438
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
evok Legal Accounting And Filing Fees
LegalAccountingAndFilingFees
138000
CY2016Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
99000
CY2015Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
170000
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
34067
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
41176
CY2016Q3 us-gaap Share Based Compensation
ShareBasedCompensation
452236
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
371675
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y11D

Files In Submission

Name View Source Status
0001564590-16-028633-index-headers.html Edgar Link pending
0001564590-16-028633-index.html Edgar Link pending
0001564590-16-028633.txt Edgar Link pending
0001564590-16-028633-xbrl.zip Edgar Link pending
evok-10q_20160930.htm Edgar Link pending
evok-20160930.xml Edgar Link completed
evok-20160930.xsd Edgar Link pending
evok-20160930_cal.xml Edgar Link unprocessable
evok-20160930_def.xml Edgar Link unprocessable
evok-20160930_lab.xml Edgar Link unprocessable
evok-20160930_pre.xml Edgar Link unprocessable
evok-ex311_10.htm Edgar Link pending
evok-ex312_9.htm Edgar Link pending
evok-ex321_6.htm Edgar Link pending
evok-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending